These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27229901)

  • 21. Insight into extravasation and internalization of nanoparticles.
    Park K
    J Control Release; 2015 May; 206():243. PubMed ID: 25907318
    [No Abstract]   [Full Text] [Related]  

  • 22. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
    Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.
    Varela MC; Guzmán M; Molpeceres J; del Rosario Aberturas M; Rodríguez-Puyol D; Rodríguez-Puyol M
    Eur J Pharm Sci; 2001 Feb; 12(4):471-8. PubMed ID: 11231114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticulated Nitric Oxide Donors and their Biomedical Applications.
    Seabra AB; Duran N
    Mini Rev Med Chem; 2017; 17(3):216-223. PubMed ID: 27515711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppression and rejection in human hand transplantation.
    Schneeberger S; Gorantla VS; Hautz T; Pulikkottil B; Margreiter R; Lee WP
    Transplant Proc; 2009 Mar; 41(2):472-5. PubMed ID: 19328906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell and biomaterial delivery strategies to induce immune tolerance.
    Scotland BL; Shaw JR; Dharmaraj S; Caprio N; Cottingham AL; Joy Martín Lasola J; Sung JJ; Pearson RM
    Adv Drug Deliv Rev; 2023 Dec; 203():115141. PubMed ID: 37980950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to modulate immune responses: a new frontier for gene therapy.
    Arruda VR; Favaro P; Finn JD
    Mol Ther; 2009 Sep; 17(9):1492-503. PubMed ID: 19584819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology of immunosuppressive medications used in renal diseases and transplantation.
    de Mattos AM; Olyaei AJ; Bennett WM
    Am J Kidney Dis; 1996 Nov; 28(5):631-67. PubMed ID: 9158202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Immunosuppressive Therapy in Solid Organ Transplantation.
    Holt CD
    Anesthesiol Clin; 2017 Sep; 35(3):365-380. PubMed ID: 28784214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver transplant immunosuppression during the covid-19 pandemic.
    Forns X; Navasa M
    Gastroenterol Hepatol; 2020 Oct; 43(8):457-463. PubMed ID: 32646657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
    MacPhee IA; Holt DW
    Transplantation; 2008 Jan; 85(2):163-5. PubMed ID: 18212618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunity after organ transplantation.
    Villard J
    Swiss Med Wkly; 2006 Feb; 136(5-6):71-7. PubMed ID: 16633949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression.
    Zhang C; Yan Q; Li J; Zhu Y; Zhang Y
    ACS Appl Bio Mater; 2021 Jan; 4(1):277-294. PubMed ID: 35014284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of complications from use of conventional immunosuppressants: a critical review.
    Ponticelli C; Glassock RJ
    J Nephrol; 2019 Dec; 32(6):851-870. PubMed ID: 30927190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
    Maldonado RA; LaMothe RA; Ferrari JD; Zhang AH; Rossi RJ; Kolte PN; Griset AP; O'Neil C; Altreuter DH; Browning E; Johnston L; Farokhzad OC; Langer R; Scott DW; von Andrian UH; Kishimoto TK
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E156-65. PubMed ID: 25548186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigations on the Ability of the Insular Cortex to Process Peripheral Immunosuppression.
    Bihorac J; Salem Y; Lückemann L; Schedlowski M; Doenlen R; Engler H; Mark MD; Dombrowski K; Spoida K; Hadamitzky M
    J Neuroimmune Pharmacol; 2024 Jul; 19(1):40. PubMed ID: 39078442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-based immunosuppression following liver transplantation: the plot thickens.
    Heimbach JK; Charlton MR
    Am J Transplant; 2010 Mar; 10(3):445-6. PubMed ID: 20121726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling the liver graft.
    Celaj S; Levitsky J
    Curr Opin Organ Transplant; 2021 Feb; 26(1):17-22. PubMed ID: 33278149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.
    Hunter Z; McCarthy DP; Yap WT; Harp CT; Getts DR; Shea LD; Miller SD
    ACS Nano; 2014 Mar; 8(3):2148-60. PubMed ID: 24559284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.
    Jarai BM; Stillman Z; Attia L; Decker GE; Bloch ED; Fromen CA
    ACS Appl Mater Interfaces; 2020 Sep; 12(35):38989-39004. PubMed ID: 32805901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.